How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,473 results for

First Generation Sulfonylurea

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Effect of second-generation sulfonylureas on survival in patients with diabetes mellitus after myocardial infarction (PubMed)

[57%]), 409 (19%) had DM. The 23 patients treated with first-generation sulfonylureas, biguanides, or thiazolidinediones were excluded from analyses. Among the remaining 386 patients with DM, 120 (31%) were taking second-generation sulfonylureas, 180 (47%) were taking insulin, and 86 (22%) were receiving nonpharmacological treatment. Patients with DM treated with second-generation sulfonylureas were more likely to be men and have higher creatinine clearance than those treated with insulin. After (...) Effect of second-generation sulfonylureas on survival in patients with diabetes mellitus after myocardial infarction To examine possible adverse effects of sulfonylureas on survival among patients with diabetes mellitus (DM) who experience a myocardial infarction (MI).Residents of Olmsted County, Minnesota, with an MI that met standardized criteria from January 1, 1985, through December 31, 2002, were followed up for mortality.Among 2189 patients with MI (mean+/-SD age, 68+/-14 years; 1237 men

Full Text available with Trip Pro

2009 EvidenceUpdates

42. Erythroderma (Generalized Exfoliative Dermatitis) (Overview)

Erythroderma (Generalized Exfoliative Dermatitis) (Overview) Erythroderma (Generalized Exfoliative Dermatitis): Background, Pathophysiology, Etiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache (...) =aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTEwNjkwNi1vdmVydmlldw== processing > Erythroderma (Generalized Exfoliative Dermatitis) Updated: Jun 03, 2018 Author: Sanusi H Umar, MD, FAAD; Chief Editor: Dirk M Elston, MD Share Email Print Feedback Close Sections Sections Erythroderma (Generalized Exfoliative Dermatitis) Overview Background Exfoliative dermatitis (ED) is a definitive term that refers to a scaling erythematous dermatitis involving 90% or more of the cutaneous surface. Exfoliative dermatitis is characterized by erythema and scaling involving

2014 eMedicine.com

43. Lipodystrophy, Generalized (Diagnosis)

hormones such as insulin [ , ] and growth hormone [ ] ) Lipoatrophic diabetes: Diabetes mellitus in association with lipoatrophy Classification of lipoatrophy syndromes See the list below: Congenital generalized lipoatrophy (or, Seip-Berardinelli syndrome): Autosomal recessive; generalized absence of fat within the first year of life, followed by insulin resistance, acanthosis nigricans, diabetes mellitus before adolescence; severe hypertriglyceridemia accompanied by frequent pancreatitis; high basal (...) generalized lipoatrophy Congenital generalized lipoatrophy, also known as Seip-Berardinelli syndrome, is a genetic disease with heterogeneous causes (see image below). [ , , , , ] In this syndrome, children present with a generalized absence of fat within the first year of life. This is followed by insulin resistance, acanthosis nigricans, and diabetes mellitus before adolescence. Hypertriglyceridemia is severe and is accompanied by frequent bouts of pancreatitis. Affected patients have a high basal

2014 eMedicine.com

44. Erythroderma (Generalized Exfoliative Dermatitis) (Diagnosis)

Erythroderma (Generalized Exfoliative Dermatitis) (Diagnosis) Erythroderma (Generalized Exfoliative Dermatitis): Background, Pathophysiology, Etiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache (...) =aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTEwNjkwNi1vdmVydmlldw== processing > Erythroderma (Generalized Exfoliative Dermatitis) Updated: Jun 03, 2018 Author: Sanusi H Umar, MD, FAAD; Chief Editor: Dirk M Elston, MD Share Email Print Feedback Close Sections Sections Erythroderma (Generalized Exfoliative Dermatitis) Overview Background Exfoliative dermatitis (ED) is a definitive term that refers to a scaling erythematous dermatitis involving 90% or more of the cutaneous surface. Exfoliative dermatitis is characterized by erythema and scaling involving

2014 eMedicine.com

45. Lipodystrophy, Generalized (Overview)

hormones such as insulin [ , ] and growth hormone [ ] ) Lipoatrophic diabetes: Diabetes mellitus in association with lipoatrophy Classification of lipoatrophy syndromes See the list below: Congenital generalized lipoatrophy (or, Seip-Berardinelli syndrome): Autosomal recessive; generalized absence of fat within the first year of life, followed by insulin resistance, acanthosis nigricans, diabetes mellitus before adolescence; severe hypertriglyceridemia accompanied by frequent pancreatitis; high basal (...) generalized lipoatrophy Congenital generalized lipoatrophy, also known as Seip-Berardinelli syndrome, is a genetic disease with heterogeneous causes (see image below). [ , , , , ] In this syndrome, children present with a generalized absence of fat within the first year of life. This is followed by insulin resistance, acanthosis nigricans, and diabetes mellitus before adolescence. Hypertriglyceridemia is severe and is accompanied by frequent bouts of pancreatitis. Affected patients have a high basal

2014 eMedicine.com

46. Erythroderma (Generalized Exfoliative Dermatitis) (Treatment)

Erythroderma (Generalized Exfoliative Dermatitis) (Treatment) Erythroderma (Generalized Exfoliative Dermatitis) Treatment & Management: Medical Care, Consultations, Diet Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache (...) =aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTEwNjkwNi10cmVhdG1lbnQ= processing > Erythroderma (Generalized Exfoliative Dermatitis) Treatment & Management Updated: Jun 03, 2018 Author: Sanusi H Umar, MD, FAAD; Chief Editor: Dirk M Elston, MD Share Email Print Feedback Close Sections Sections Erythroderma (Generalized Exfoliative Dermatitis) Treatment Medical Care Patients presenting acutely with exfoliative dermatitis (ED) often require admission for inpatient management because their total body functions (including intake and output) can require monitoring

2014 eMedicine.com

47. Lipodystrophy, Generalized (Treatment)

hormones such as insulin [ , ] and growth hormone [ ] ) Lipoatrophic diabetes: Diabetes mellitus in association with lipoatrophy Classification of lipoatrophy syndromes See the list below: Congenital generalized lipoatrophy (or, Seip-Berardinelli syndrome): Autosomal recessive; generalized absence of fat within the first year of life, followed by insulin resistance, acanthosis nigricans, diabetes mellitus before adolescence; severe hypertriglyceridemia accompanied by frequent pancreatitis; high basal (...) generalized lipoatrophy Congenital generalized lipoatrophy, also known as Seip-Berardinelli syndrome, is a genetic disease with heterogeneous causes (see image below). [ , , , , ] In this syndrome, children present with a generalized absence of fat within the first year of life. This is followed by insulin resistance, acanthosis nigricans, and diabetes mellitus before adolescence. Hypertriglyceridemia is severe and is accompanied by frequent bouts of pancreatitis. Affected patients have a high basal

2014 eMedicine.com

48. Lipodystrophy, Generalized (Follow-up)

hormones such as insulin [ , ] and growth hormone [ ] ) Lipoatrophic diabetes: Diabetes mellitus in association with lipoatrophy Classification of lipoatrophy syndromes See the list below: Congenital generalized lipoatrophy (or, Seip-Berardinelli syndrome): Autosomal recessive; generalized absence of fat within the first year of life, followed by insulin resistance, acanthosis nigricans, diabetes mellitus before adolescence; severe hypertriglyceridemia accompanied by frequent pancreatitis; high basal (...) generalized lipoatrophy Congenital generalized lipoatrophy, also known as Seip-Berardinelli syndrome, is a genetic disease with heterogeneous causes (see image below). [ , , , , ] In this syndrome, children present with a generalized absence of fat within the first year of life. This is followed by insulin resistance, acanthosis nigricans, and diabetes mellitus before adolescence. Hypertriglyceridemia is severe and is accompanied by frequent bouts of pancreatitis. Affected patients have a high basal

2014 eMedicine.com

49. Erythroderma (Generalized Exfoliative Dermatitis) (Follow-up)

Erythroderma (Generalized Exfoliative Dermatitis) (Follow-up) Erythroderma (Generalized Exfoliative Dermatitis) Treatment & Management: Medical Care, Consultations, Diet Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache (...) =aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTEwNjkwNi10cmVhdG1lbnQ= processing > Erythroderma (Generalized Exfoliative Dermatitis) Treatment & Management Updated: Jun 03, 2018 Author: Sanusi H Umar, MD, FAAD; Chief Editor: Dirk M Elston, MD Share Email Print Feedback Close Sections Sections Erythroderma (Generalized Exfoliative Dermatitis) Treatment Medical Care Patients presenting acutely with exfoliative dermatitis (ED) often require admission for inpatient management because their total body functions (including intake and output) can require monitoring

2014 eMedicine.com

50. Study of Myocet Plus Cyclophosphamide Plus Metformin Versus Myocet Plus Cyclophosphamide in First Line Treatment of HER2 Negative Metastatic Breast Cancer Patients

Study of Myocet Plus Cyclophosphamide Plus Metformin Versus Myocet Plus Cyclophosphamide in First Line Treatment of HER2 Negative Metastatic Breast Cancer Patients Myocet + Cyclophosphamide + Metformin Vs Myocet + Cyclophosphamide in 1st Line Treatment of HER2 Neg. Metastatic Breast Cancer Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved (...) . ClinicalTrials.gov Identifier: NCT01885013 Recruitment Status : Completed First Posted : June 24, 2013 Last Update Posted : January 1, 2016 Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori Information provided by (Responsible Party): Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori Study Details Study Description Go to Brief Summary: This is a phase II comparative randomized clinical trial. Eligible patients will be randomized (1:1) to: Arm A: Myocet plus Cyclofosfamide

2013 Clinical Trials

51. A First-time-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of GSK189075A in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus

A First-time-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of GSK189075A in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus A First-time-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of GSK189075A in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer (...) to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A First-time-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of GSK189075A in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus The safety and scientific validity of this study

2012 Clinical Trials

52. Cardiomyocyte sulfonylurea receptor 2-KATP channel mediates cardioprotection and ST segment elevation (PubMed)

Cardiomyocyte sulfonylurea receptor 2-KATP channel mediates cardioprotection and ST segment elevation Sulfonylurea receptor-containing ATP-sensitive potassium (K(ATP)) channels have been implicated in cardioprotection, but the cell type and constitution of channels responsible for this protection have not been clear. Mice deleted for the first nucleotide binding region of sulfonylurea receptor 2 (SUR2) are referred to as SUR2 null since they lack full-length SUR2 and glibenclamide-responsive K (...) (ATP) channels in cardiac, skeletal, and smooth muscle. As previously reported, SUR2 null mice develop electrocardiographic changes of ST segment elevation that were shown to correlate with coronary artery vasospasm. Here we restored expression of the cardiomyocyte SUR2-K(ATP) channel in SUR2 null mice by generating transgenic mice with ventricular cardiomyocyte-restricted expression of SUR2A. Introduction of the cardiomyocyte SUR2A transgene into the SUR2 null background restored functional

Full Text available with Trip Pro

2010 American Journal of Physiology - Heart and Circulatory Physiology

53. Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Sulfonylurea

Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Sulfonylurea Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Sulfonylurea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study (...) Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Sulfonylurea The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S

2010 Clinical Trials

54. The Effect of Vildagliptin Based Treatment Versus Sulfonylurea on Glycemic Variability, Oxidative Stress, GLP-1, and Endothelial Function in Patients With Type 2 Diabetes

been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01404676 Recruitment Status : Completed First Posted : July 28, 2011 Last Update Posted : September 18, 2018 Sponsor: Samsung Medical Center Collaborator: Novartis Information provided by (Responsible Party): Samsung Medical Center Study Details Study Description Go to Brief Summary: The effect of vildagliptin based treatment versus sulfonylurea based treatment on glycemic variability, oxidative (...) The Effect of Vildagliptin Based Treatment Versus Sulfonylurea on Glycemic Variability, Oxidative Stress, GLP-1, and Endothelial Function in Patients With Type 2 Diabetes The Effect of Vildagliptin Based Treatment Versus Sulfonylurea on Glycemic Variability, Oxidative Stress, GLP-1, and Endothelial Function in Patients With Type 2 Diabetes - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search

2010 Clinical Trials

55. Hypoglycemia- and Weight-related Quality of Life in Patients With Diabetes Mellitus Type 2 on Sulfonylurea Derivatives.

number of saved studies (100). Please remove one or more studies before adding more. Hypoglycemia- and Weight-related Quality of Life in Patients With Diabetes Mellitus Type 2 on Sulfonylurea Derivatives. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01244646 Recruitment Status : Terminated First (...) . For general information, Layout table for eligibility information Ages Eligible for Study: 35 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Sampling Method: Probability Sample Study Population General practitioners, group practices in primary care, pharmacists Criteria Inclusion Criteria: Diabetes Mellitus Type 2 for > 6 months on treatment with only metformin for >4 weeks HbA1c value >7.0 and therefore a sulfonylurea derivative is added Able to complete

2010 Clinical Trials

56. A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients

studies (100). Please remove one or more studies before adding more. A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01242215 Recruitment Status : Completed First Posted : November 16, 2010 (...) Astellas Pharma Inc More Information Go to Additional Information: Layout table for additonal information Responsible Party: Astellas Pharma Inc ClinicalTrials.gov Identifier: Other Study ID Numbers: 1941-CL-0109 First Posted: November 16, 2010 Last Update Posted: January 20, 2016 Last Verified: January 2016 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: Undecided Keywords provided by Astellas Pharma Inc: ASP1941 Diabetes mellitus sulfonylurea Additional relevant MeSH terms

2010 Clinical Trials

57. Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search (...) for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been

2010 Clinical Trials

58. Adding Sitagliptin or Pioglitazone to Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin and Sulfonylurea

or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 20 Years to 80 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Type 2 diabetes patients who were treated with stable doses of sulfonylurea and metformin to their half maximally dose (sulfonylureas > half maximal dose, and metformin > 1500 mg/d) for > 10 weeks (...) Adding Sitagliptin or Pioglitazone to Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin and Sulfonylurea Adding Sitagliptin or Pioglitazone to Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin and Sulfonylurea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2010 Clinical Trials

59. The Pharmacokinetic Interaction Between CKD-501 and Sulfonylurea

Interaction Between CKD-501 and Sulfonylurea (CKD-501 DDI) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01133431 Recruitment Status : Completed First Posted : May 28, 2010 Last Update Posted : December 10, 2010 Sponsor: Chong Kun Dang Pharmaceutical Information provided by: Chong Kun Dang Pharmaceutical (...) The Pharmacokinetic Interaction Between CKD-501 and Sulfonylurea The Pharmacokinetic Interaction Between CKD-501 and Sulfonylurea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. The Pharmacokinetic

2010 Clinical Trials

60. A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy

A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration (...) or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy The safety and scientific validity of this study is the responsibility of the study sponsor and investigators

2010 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>